Drug study offers hope for improved lung-cancer survival after surgery
A new Yale-led study finds improved survival rates and reduced risk of recurrence of non-small cell lung cancer with the drug osimertinib following surgery.
Source: Yale Science and Health News - Category: Universities & Medical Training Source Type: news
More News: Cancer | Cancer & Oncology | Health | Lung Cancer | Non-Small Cell Lung Cancer | Science | Study | Universities & Medical Training | Yale